S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
NYSEAMERICAN:OGEN

Oragenics Stock Forecast, Price & News

$0.93
-0.02 (-2.11 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.90
Now: $0.93
$1.03
50-Day Range
$0.42
MA: $0.44
$0.54
52-Week Range
$0.36
Now: $0.93
$2.09
Volume30.38 million shs
Average Volume73.54 million shs
Market Capitalization$71.81 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

MarketRank

Overall MarketRank

0.65 out of 5 stars

Medical Sector

1048th out of 1,480 stocks

Pharmaceutical Preparations Industry

484th out of 612 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone813 286 7900
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.23 per share

Profitability

Net Income$-15,570,000.00

Miscellaneous

Market Cap$71.81 million
Next Earnings Date3/3/2021 (Estimated)
OptionableNot Optionable
$0.93
-0.02 (-2.11 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

How has Oragenics' stock price been impacted by Coronavirus (COVID-19)?

Oragenics' stock was trading at $0.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OGEN stock has increased by 54.8% and is now trading at $0.9287.
View which stocks have been most impacted by COVID-19
.

Is Oragenics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Oragenics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGEN, but not buy additional shares or sell existing shares.
View analyst ratings for Oragenics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Oragenics?

Wall Street analysts have given Oragenics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oragenics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oragenics' next earnings date?

Oragenics is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Oragenics
.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) announced its quarterly earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.01.
View Oragenics' earnings history
.

When did Oragenics' stock split? How did Oragenics' stock split work?

Oragenics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Celsion (CLSN), Jaguar Health (JAGX), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 61, Pay $488.39k)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 64, Pay $313.31k)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 49, Pay $244.92k)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

Who are Oragenics' major shareholders?

Oragenics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sara Bay Financial (1.30%). Company insiders that own Oragenics stock include Joseph Hernandez and Robert C Koski.
View institutional ownership trends for Oragenics
.

Which major investors are selling Oragenics stock?

OGEN stock was sold by a variety of institutional investors in the last quarter, including Sara Bay Financial. Company insiders that have sold Oragenics company stock in the last year include Joseph Hernandez, and Robert C Koski.
View insider buying and selling activity for Oragenics
or view top insider-selling stocks.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.93.

How big of a company is Oragenics?

Oragenics has a market capitalization of $71.81 million. The biotechnology company earns $-15,570,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Oragenics employs 7 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at 813 286 7900 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.